Table 2 Recommended immunizations against invasive pneumococcal disease using the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23) for adults aged ≥19 years with functional or anatomic asplenia [17]
From: Recurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia
Vaccination status | PCV13 | PPV23 | Antibody measurement |
|---|---|---|---|
Pneumococcal vaccine-naïve | 1 dose of PCV13 | 1 dose of PPV23 ≥ 8 weeks after PCV13 | Prior to revaccination with PPV23 |
Revaccination with PPV23 ≥ 5 years after last PPV23 | |||
Earlier vaccinated with PPV23 | 1 dose of PCV13 ≥ 1 year after last PPV23 | Revaccination with PPV23 ≥ 8 weeks after PCV13 and ≥ 5 years after last PPV23 | Prior to revaccination with PPV23 |